Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA approves J&J’s Tremfya self-injection pen for psoriasis

January 30, 2019 By Nancy Crotti

FDA has approved Johnson & Johnson’s patient-controlled injector for Tremfya, a treatment for adults with moderate to severe plaque psoriasis.

The self-injection approval may help Tremfya compete with AbbVie’s  (NYSE:ABBV) Humira pen, which was previously approved for self-injection by psoriasis patients.

Made by J&J subsidiary Janssen Pharmaceuticals (Horsham, Penn.), Tremfya is a biologic therapy that selectively blocks only IL-23, a cytokine that plays a key role in plaque psoriasis, according to Janssen. Tremfya is administered as a 100 mg subcutaneous injection every eight weeks, following two starter doses at weeks 0 and 4.

FDA cleared J&J’s Tremfya in 2017. In clinical studies, patients receiving Tremfya experienced significant improvement in skin clearance and greater improvement in symptoms of plaque psoriasis including itch, pain, stinging, burning and skin tightness when compared with placebo at week 16, according to Janssen.

Filed Under: Auto-injectors, Drug-Device Combinations, Food & Drug Administration (FDA), Uncategorized Tagged With: AbbVie, FDA, Janssen Pharmaceuticals, johnsonandjohnson

IN CASE YOU MISSED IT

  • Eitan Group signs service agreement with Integrated Medical Systems
  • Beta Bionics’ bionic pancreas wins breakthrough status from FDA
  • FDA details framework for abbreviated 510(k) medical device review pathway
  • Aptar wins FDA clearance for ready-to-use seizure treatment device
  • Proteus Digital Health restructuring amid reported funding woes
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookDrug Delivery Business News
Follow us on Twitter@DrugDeliveryNow
Connect with us on LinkedInLinkedIn

Copyright © 2019 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS